Creative Biolabs

Advancements in Preclinical Models for Batten Disease Research

Batten Disease is a group of rare, fatal, inherited disorders of the nervous system, also known as neuronal ceroid lipofuscinosis (NCL), and encompasses a group of inherited neurodegenerative disorders primarily affecting children. This devastating condition is characterized by the accumulation of lipopigments in cells throughout the body, leading to progressive neurological deterioration and premature death. Despite being rare, Batten disease poses significant challenges for affected individuals and their families, necessitating intensive research efforts to develop effective treatments.

Over the years, significant progress has been made in developing and refining preclinical models for Batten disease, offering insights into disease pathogenesis and paving the way for innovative therapeutic strategies. Creative Biolabs - a trailblazer in preclinical research - has long been dedicated to investigating Batten disease. We explore the latest updates and advancements in preclinical models for Batten disease research, highlighting the contributions of these models to our understanding of the disease and the development of novel treatments.

Understanding Batten Disease

Batten disease, which belongs to a group of life-shortening conditions, is recognized among the most common neurodegenerative diseases in children. These are inherited mutations that adversely affect the normal functioning of lysosomes – the waste disposal system of cells. This malfunction precipitates an accumulation of proteins and lipids, inflicting gradual damage on cells, particularly neurons, and leading to their premature death.

Primarily affecting pediatric patients, Batten disease is characterized by symptoms such as vision loss, seizures, delay and eventual loss of skills previously attained, and severe cognitive impairment, leading to a life span that rarely extends beyond late teens or early twenties.

Cellular functions of the Batten disease proteins. (Brudvig, Jon J., and Jill M. Weimer, 2022)Fig. 1 Cellular functions of the Batten disease proteins.1

A compelling aspect of the research into Batten disease is the range of genetic mutations implicated (CLN1-8、CLN10-14). These mutations all fundamentally disrupt the normal waste clearance, but each variant affects different proteins and ensues at different life stages - presenting a formidable challenge for researchers.

Though Batten disease is rare, its consequences are magnified by its potent lethality, underscoring the need for a comprehensive understanding and effective treatment strategies. Creative Biolabs offers advanced technologies and services to help researchers break through this genetic puzzle.

Our Services Descriptions
Animal Models The animal model development service for Batten disease provided by Creative Biolabs encompasses a comprehensive approach, starting from model design and development to phenotypic characterization. Our team of highly skilled scientists collaborates closely with clients to develop and optimize animal models that accurately recapitulate the disease phenotype, thereby facilitating the discovery and validation of therapeutic targets.
Neurological Disease-based Assay Creative Biolabs presents an extensive selection of cutting-edge in vitro assay services focused on neurological diseases including Batten disease. Our dedicated team collaborates closely with researchers to design customized neural cell assays tailored to their specific questions.
Batten Disease (BD) Drug Discovery Service Creative Biolabs is well-known in the field of neuroscience and has completed many innovative projects in this field. Now we provide one-stop research services against Batten disease for our clients all over the world.

Preclinical Models for Batten Disease Research

Preclinical models for Batten disease research span a wide range of experimental systems, including cell-based models, animal models, and more recently, advanced in vitro and in vivo models. These models faithfully reproduce key aspects of the pathophysiology of Batten disease, enabling researchers to study disease mechanisms, screen potential therapies, and evaluate treatment efficacy.

  • Cell-based models: such as patient-derived iPSC and neuronal cell lines, provide valuable platforms for studying disease mechanisms and testing therapeutic compounds. By differentiating iPSC into neuronal lineages, researchers can mimic disease-related processes such as lysosomal dysfunction, neuronal degeneration and neuroinflammation in a controlled in vitro environment.
Cat. No Product Name Types
NRZP-0323-ZP19 iNeu™ Human iPSC, Batten disease iPSC
  • Animal models: various animal models have been developed to summarize the different subtypes of Batten disease, each of which exhibits different clinical and neuropathological features.
    • Mouse models, including Cln1, Cln2 and Cln3 knockout mice, have been widely used to study different forms of Batten disease. These models exhibit features of Batten disease, including lysosomal storage pathology, neuroinflammation, motor dysfunction, and cognitive deficits.
    • Large animal models, such as the sheep model of CLN5 Batten disease, have been used to evaluate gene therapy strategies using AAV vectors, demonstrating promising results in terms of transgene expression, lysosomal correction, and neurologic improvement. Similarly, canine models of Batten disease have played an important role in testing new therapies, such as enzyme replacement therapy and stem cell transplantation.
  • Advanced in vitro and in vivo platforms: researchers are increasingly utilizing advanced in vitro and in vivo platforms to improve the fidelity and relevance of preclinical studies in Batten disease research.
    • Organoid models, such as brain organoid cultures hold promise for the study of neurodevelopmental disorders and neurodegenerative diseases, including Batten disease.
    • Microfluidic devices provide precise control of the cellular microenvironment, and these platforms can be used to model various aspects of Batten disease pathology, such as neural cell death, lysosomal dysfunction, and neuroinflammation, enabling researchers to identify new drug targets and evaluate therapeutic interventions in a cost-effective manner.

Therapeutic Strategies

The rapid advancements in preclinical models for Batten disease have positively influenced our understanding of its pathogenesis. Nonetheless, the complex heterogeneity of Batten disease commands a continually evolving landscape of more refined and accurate models. Hence, it's necessary to develop innovative models to explore novel therapeutic targets. These efforts have yielded promising candidates across multiple cellular pathways, including lysosomal function, autophagy, oxidative stress, and neuroinflammation.

  • One target of interest is the lysosomal enzyme palmitoyl protein thioesterase 1 (PPT1) encoded by the CLN1 gene.
Cat. No Product Name Clonality Applications
NAB20102070CR Mouse Anti-PPT1 Monoclonal Antibody (CBP2992) Monoclonal WB; ELISA
NAB2012929LS Mouse Anti-Human PPT1 Monoclonal Antibody (CBP3984) Monoclonal WB
NRZP-0822-ZP1155 NeuroMab™ Anti-PPT1 Antibody, Clone N33107P (CBP9437) Monoclonal WB; IHC; IHC-P
NAB-08-PZ327 NeuroMab™ Rabbit Anti-CLN5 Monoclonal Antibody (CBP1818) Monoclonal IHC-P; WB; ICC; IF
NRP-0422-P79 NeuroMab™ Anti-CLN3, Clone N380/87 (CBP8180) Monoclonal WB; IHC; ICC
NRZP-0423-ZP79 NeuroMab™ Anti-CLN3 BBB Shuttle Antibody, Clone N380/87 Monoclonal WB; IHC; ICC
NRP-0422-P80 NeuroMab™ Anti-CLN6, Clone N400/24 (CBP8181) Monoclonal WB; IHC; ICC
NRZP-0423-ZP80 NeuroMab™ Anti-CLN6 BBB Shuttle Antibody, Clone N400/24 Monoclonal WB; IHC; ICC
  • Additional well-studied targets include targeting the regulation of key signaling nodes associated with neuroinflammation, excitotoxicity and oxidative stress.

Within the intricate web of Batten Disease pathology lie a multitude of potential therapeutic targets, each holding the promise of halting or even reversing disease progression. From modulating lysosomal function to targeting aberrant protein aggregation, researchers are exploring a diverse array of strategies aimed at mitigating the devastating effects of the disease. Emerging technologies such as gene therapy, enzyme replacement therapy, and small molecule inhibitors offer new avenues for intervention.

At Creative Biolabs, we embrace the relentless pursuit of scientific exploration, underpinning the urgent need to expand the landscape of preclinical models for Batten disease.


  1. Brudvig, Jon J., and Jill M. Weimer. "On the cusp of cures: breakthroughs in Batten disease research." Current Opinion in Neurobiology 72 (2022): 48-54.
For Research Use Only. Not For Clinical Use.
Fill out this form for a quote Inquiry Form Send Inquiry
Inquiry Basket

Send inquiry